Addition of sodium glucose cotransporter 2 (SGLT2) inhibitor to glucagon-like peptide-1 (GLP-1) receptor agonist therapy in obese people with Type 2 diabetes and suboptimal glycaemic control

被引：0
|
作者：
Curtis, L. R. [1 ]
Walker, J. I. [1 ]
Knott, J. [1 ]
Partridge, H. L. [1 ]
机构：
[1] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Diabet & Endocrine Ctr, Bournemouth, Dorset, England
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P529
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [41] INCIDENCE OF PRIMARY NONADHERENCE TO SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ( SGLT2I) AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN AN INTEGRATED HEALTHCARE SYSTEM
    Luo, Jing
    Feldman, Robert
    Rothenberger, Scott
    Fischer, Michael A.
    Korytkowski, Mary
    Gellad, Walid
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (SUPPL 1) : S84 - S85
  • [42] Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence
    Arévalo-Lorido J.C.
    Gómez J.C.
    Huelgas R.G.
    de Lucas D.G.
    Polo L.M.
    Aguilar J.M.V.
    Muñoz J.E.
    High Blood Pressure & Cardiovascular Prevention, 2018, 25 (4) : 417 - 420
  • [43] Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
    Pierre Gourdy
    Patrice Darmon
    François Dievart
    Jean-Michel Halimi
    Bruno Guerci
    Cardiovascular Diabetology, 22
  • [44] Near-normalisation of glycaemic control in patients with type 2 diabetes with a glucagon-like peptide-1 receptor agonist in combination with exercise
    Mensberg, P. F.
    Nyby, S.
    Jorgensen, P. G.
    Storgaard, H.
    Sivertsen, J.
    Jensen, M. T.
    Holst, J. J.
    Kiens, B.
    Richter, E. A.
    Knop, F. K.
    Vilsboll, T.
    DIABETOLOGIA, 2014, 57 : S376 - S376
  • [45] Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    Nauck, M. A.
    Vardarli, I.
    Deacon, C. F.
    Holst, J. J.
    Meier, J. J.
    DIABETOLOGIA, 2011, 54 (01) : 10 - 18
  • [46] Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
    Gourdy, Pierre
    Darmon, Patrice
    Dievart, Francois
    Halimi, Jean-Michel
    Guerci, Bruno
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [47] Modern possibilities of pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1)
    Shestakova, M., V
    Vikulova, O. K.
    DIABETES MELLITUS, 2007, 10 (01): : 9 - 15
  • [48] CJC-1131 -: Agent for type 2 diabetes glucagon-like peptide-1 (GLP-1) analogue
    Davies, SJ
    Martín, L
    Castañer, RM
    DRUGS OF THE FUTURE, 2005, 30 (06) : 553 - 557
  • [49] Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
    Hong, Dongzhe
    Si, Lei
    Jiang, Minghuan
    Shao, Hui
    Ming, Wai-kit
    Zhao, Yingnan
    Li, Yan
    Shi, Lizheng
    PHARMACOECONOMICS, 2019, 37 (06) : 777 - 818
  • [50] Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
    Dongzhe Hong
    Lei Si
    Minghuan Jiang
    Hui Shao
    Wai-kit Ming
    Yingnan Zhao
    Yan Li
    Lizheng Shi
    PharmacoEconomics, 2019, 37 : 777 - 818
12345